- Home
- Equipment
- usa new york
- potential ad therapeutic
Show results for
Refine by
Potential Ad Therapeutic Equipment Supplied In Usa New York
11 equipment items found
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid potential immune responses that may ...
Manufactured by:Altucell, Inc. based inNew York, NEW YORK (USA)
Encapsulated cell therapy is an emerging area of biopharmaceutical research that aims to unleash the therapeutic potential of cells to treat serious diseases without the need for immunosuppression. Altucell has developed patented, proprietary engineered cells that are combined with a patented encapsulation technology to create effective ...
Manufactured by:UroGen Pharma, Inc. based inPrinceton, NEW YORK (USA)
UroGen is evaluating UGN-301, our in-licensed anti-CTLA-4 antibody (zalifrelimab), as a monotherapy and as combination therapy with ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelociMab is a group of technologies that allow us to move with unprecedented speed from identification of a therapeutic antibody into clinical studies. VelociMab enables the high-throughput screening of potential therapeutic antibodies and the rapid generation of cell lines for recombinant human antibodies. It allows researchers to go from mouse immunization to production cell line bioreactor ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
Manufactured by:Ampersand Biosciences based inLake Clear, NEW YORK (USA)
Angiopoietin-related protein 7 (ANGPTL7), UniProt # O43827, is a 40kDa protein initially discovered in the cornea stromal layer. Increased levels have been observed in glaucoma and ANGPTL7 has been associated with various cancers including hepatic cancer metastasis. Studies have shown plasma levels are increased in obesity making it a potential therapeutic ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 expression has been reported on the cancer stem cells ...
by:Firefly Neuroscience, Inc. based inKenmore, NEW YORK (USA)
Firefly Neuroscience's Brain Network Analytics (BNA™) offers an innovative approach to neurological diagnostics and treatment. Utilizing a vast proprietary database of more than 77,000 EEG scans across twelve disorders, BNA™ leverages advanced AI to facilitate early detection of subtle neurological anomalies. This technology enables the development of personalized treatment plans, ...
by:Valo Health, Inc. based inBoston, MASSACHUSETTS (USA)
Opal is the first end-to-end integrated drug discovery & development platform. Traditional, linear approaches to target discovery and drug development have created sub-optimized systems that are intrinsically disintegrated and ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...